The raised guidance and strong investment pipeline suggest continued AFFO growth. Watch for the conversion of the $846M UK mortgage loan into a long-term lease and further accretive capital deployment. The Genesis resolution removes a key overhang.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omega Healthcare reported Q3 2026 AFFO of $0.82 per share, beating the $0.78 consensus estimate, and raised its full-year 2026 AFFO guidance midpoint to $3.29 from $3.24. The company completed $946 million in investments since quarter-end, including an $846 million UK mortgage loan, and finalized the Genesis bankruptcy sale with $149.5 million in loan repayments received. Operator coverage improved to 2.03x EBITDARM, and the quarterly dividend was increased to $0.68 per share.
Key Financial Metrics
Key Facts
- Q3 2026 AFFO of $262M, or $0.82 per diluted share, vs $0.79 in Q3 2025
- Full-year 2026 AFFO guidance raised to $3.28-$3.30 per share from $3.22-$3.26
- Completed $946M in investments since quarter-end, including $846M UK mortgage loan
- Genesis bankruptcy sale finalized; Omega received $149.5M in DIP and term loan repayments
- Quarterly dividend increased to $0.68 per share from $0.67
- Operator EBITDARM coverage improved to 2.03x for the twelve months ended June 30, 2026
- Net income of $87M, or $0.27 per diluted share, vs $185M in Q3 2025 (includes $60M in acquisition costs)
- Total revenues of $340.6M, up 9.3% from $311.6M in Q3 2025
- Issued 4.7M common shares in Q3 for gross proceeds of $234M
- Debt reduced to $4.1B with $2.0B undrawn credit facility capacity
Financial Impact
AFFO beat consensus by 5.1%; guidance midpoint raised by 5 cents; $946M in post-quarter investments including $846M UK loan at 8.72% interest
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Triple-Net | $321.9M | +3.8% |
| Operating | $9.7M | Not reported |
Risk Factors
- Operator bankruptcies or rent defaults could disrupt cash flows
- Interest rate changes may impact borrowing costs and investment yields
- Foreign currency fluctuations on UK and Canadian investments
- Regulatory changes in Medicaid/Medicare reimbursement could pressure operator margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000888491-26-000028 |
| Document: ohi-20261103x8k.htm | 0000888491-26-000028 |
| Document: 0000888491-26-000028-index-headers.html | 0000888491-26-000028 |
| Document: 0000888491-26-000028-index.html | 0000888491-26-000028 |
| Document: 0000888491-26-000028.txt | 0000888491-26-000028 |
| 8-K Data (Synthetic) | 0000888491-26-000028 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 1d ago | 8-K | $47.53 | awaiting T+5 | awaiting T+5 | $47.53 (−0.00%) |
Oct 27, 2026 8d ago | Institutional Cluster | $45.64 $49.17 | ▲ +7.73% | ▲ +8.45% | $47.53 (+4.14%) |
Oct 27, 2026 8d ago | SC 13G/A | $45.64 $49.17 | ▲ +7.73% | ▲ +8.45% | $47.53 (+4.14%) |
Oct 16, 2026 19d ago | Institutional Cluster | $45.64 $46.23 | ▲ +1.29% | ▲ +1.72% | $47.53 (+4.14%) |
Oct 5, 2026 4w ago | 8-K | $45.36 $45.17 | ▼ −0.42% | ▼ −0.84% | $47.53 (+4.78%) |
Oct 1, 2026 4w ago | 8-K | $45.23 $44.14 | ▼ −2.41% | ▼ −3.71% | $47.53 (+5.09%) |
Apr 21, 2026 28w ago | DEFA14A | $45.81 $47.42 | ▲ +3.51% | ▲ +2.43% | $47.53 (+3.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers